Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Investment report on Array BioPharma

Investment report on Array BioPharma

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

EpiCept announces U.K. launch of Ceplene

EpiCept announces U.K. launch of Ceplene

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

Researchers identify new strategy for treating acute myeloid leukemia

Researchers identify new strategy for treating acute myeloid leukemia

Harnessing body's own natural killer cells to battle cancer in children

Harnessing body's own natural killer cells to battle cancer in children

Investment report on Sunesis Pharmaceuticals

Investment report on Sunesis Pharmaceuticals

New gateway may be lifesaver for patients with AML: Study

New gateway may be lifesaver for patients with AML: Study

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Platelet dosage can be lowered in transfusions for cancer and bone-marrow transplant patients

Platelet dosage can be lowered in transfusions for cancer and bone-marrow transplant patients

Alison Walker selected to receive ASH-AMFDP Award

Alison Walker selected to receive ASH-AMFDP Award

Vion Pharmaceuticals' Onrigin SPA: FDA responds

Vion Pharmaceuticals' Onrigin SPA: FDA responds

EpiCept provides business update and fourth-quarter financial highlights

EpiCept provides business update and fourth-quarter financial highlights

Researchers find gene mutations that may provide clues for treating AML patients

Researchers find gene mutations that may provide clues for treating AML patients

Aprea's AML treatment receives EMEA recommendation for orphan drug status

Aprea's AML treatment receives EMEA recommendation for orphan drug status

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation